Read the full report: https://www.reportlinker.com/p05227057
GlobalData’s epidemiological analysis is supported by the use of country-specific prevalence data from epidemiological studies published in peer-reviewed journals. GlobalData epidemiologists used uniform methodology across the markets to forecast the diagnosed prevalent cases of DME among the diagnosed diabetic retinopathy population and the total prevalent cases of ME following BRVO and CRVO, to allow for a meaningful comparison of the disease populations across these markets.
In the 7MM, GlobalData epidemiologists forecast that the diagnosed prevalent cases of DME in the diagnosed retinopathy population will grow by 31.29% over the forecast period, at an Annual Growth Rate (AGR) of 3.13%, from 980,030 cases in 2016 to 1,286,637 cases by 2026. The total prevalent cases of ME following BRVO in the 7MM increased from 307,341 total prevalent cases in 2016 to 347,397 total prevalent cases in 2026. The total prevalent cases of ME following CRVO in the 7MM increased from 125,326 total prevalent cases in 2016 to 149,226 total prevalent cases in 2026, at an AGR of 1.91% during the forecast period.
Scope
– The Macular edema (ME) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for ME in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of DME among the diagnosed diabetic retinopathy population, diagnosed prevalent cases of clinically significant DME among the diagnosed DME population, and the total prevalent cases of ME following BRVO and CRVO segmented by sex and age (ages 20 years and older) in these markets.
– The ME epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
– The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy
The ME EpiCast report will allow you to –
– Develop business strategies by understanding the trends shaping and driving the global ME market.
– Quantify patient populations in the global ME market to improve product design, pricing, and launch plans.
– Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for ME therapeutics in each of the markets covered.
– Understand magnitude of ME population by age and sex.
Read the full report: https://www.reportlinker.com/p05227057
GOT NEWS? click here
Google News, Bing News, Yahoo News, 200+ publications
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
View original content:http://www.prnewswire.com/news-releases/epicast-report-macular-edema—epidemiology-forecast-to-2026-300564863.html
SOURCE Reportlinker
